BioCentury | Jul 30, 2007
Regulation

GPC's painful day

...disease-related pain after 50 of 380 planned patients had enrolled. JMAT then licensed satraplatin to NeoTherapeutics Inc....
BioCentury | Jul 30, 2007
Regulation

GPC chronicles

...regained the program in 2003 after PanTherix did not fulfill diligence obligations. E. 10/1/02 - NeoTherapeutics...
BioCentury | Jul 2, 2007
Company News

GPC Biotech, Pharmion, Spectrum Pharmaceuticals, Yakult deal

...cancer (HRPC) in patients who have failed prior chemotherapy. GPC in-licensed satraplatin from SPPI (then NeoTherapeutics Inc....
BioCentury | Mar 14, 2005
Strategy

Burn free discovery

...clinical development team, after which it in-licensed a Phase III cancer compound, satraplatin , from NeoTherapeutics Inc....
BioCentury | Sep 6, 2004
Strategy

Back to School 2004: Asset accumulation

...Satraplatin .” In October 2002, GPC in-licensed satraplatin, an oral platinum therapy for cancer, from NeoTherapeutics Inc....
...$18.1M (PIPE) from Altana Clinical devt team from internal efforts 2002 Satraplatin from Spectrum (formerly NeoTherapeutics...
...$18.1M (PIPE) from Altana Clinical devt team from internal efforts 2002 Satraplatin from Spectrum (formerly NeoTherapeutics...
BioCentury | Jun 9, 2003
Product Development

Visibility for Europe's cancer plays

...III data at ASCO on its satraplatin oral platinum cancer therapy, which is partnered with NeoTherapeutics Inc....
BioCentury | May 19, 2003
Finance

Ebb & Flow

...initial Phase II data in June for satraplatin , an oral platinum chemotherapeutic in-licensed from NeoTherapeutics...
BioCentury | Apr 21, 2003
Finance

Ebb & Flow

...to investors about its new focus on satraplatin , an oral platinum chemotherapeutic in-licensed from NeoTherapeutics...
BioCentury | Dec 9, 2002
Clinical News

NeoTherapeutics preclinical data

...effects associated with Ritalin. Data were presented at the Society for Neuroscience meeting in Orlando. NeoTherapeutics Inc....
BioCentury | Dec 9, 2002
Clinical News

NeoTherapeutics preclinical data

...antipsychotic treatments. NEOT said both compounds had improved safety profiles compared to clozapine and risperidone. NeoTherapeutics Inc....
Items per page:
1 - 10 of 143
BioCentury | Jul 30, 2007
Regulation

GPC's painful day

...disease-related pain after 50 of 380 planned patients had enrolled. JMAT then licensed satraplatin to NeoTherapeutics Inc....
BioCentury | Jul 30, 2007
Regulation

GPC chronicles

...regained the program in 2003 after PanTherix did not fulfill diligence obligations. E. 10/1/02 - NeoTherapeutics...
BioCentury | Jul 2, 2007
Company News

GPC Biotech, Pharmion, Spectrum Pharmaceuticals, Yakult deal

...cancer (HRPC) in patients who have failed prior chemotherapy. GPC in-licensed satraplatin from SPPI (then NeoTherapeutics Inc....
BioCentury | Mar 14, 2005
Strategy

Burn free discovery

...clinical development team, after which it in-licensed a Phase III cancer compound, satraplatin , from NeoTherapeutics Inc....
BioCentury | Sep 6, 2004
Strategy

Back to School 2004: Asset accumulation

...Satraplatin .” In October 2002, GPC in-licensed satraplatin, an oral platinum therapy for cancer, from NeoTherapeutics Inc....
...$18.1M (PIPE) from Altana Clinical devt team from internal efforts 2002 Satraplatin from Spectrum (formerly NeoTherapeutics...
...$18.1M (PIPE) from Altana Clinical devt team from internal efforts 2002 Satraplatin from Spectrum (formerly NeoTherapeutics...
BioCentury | Jun 9, 2003
Product Development

Visibility for Europe's cancer plays

...III data at ASCO on its satraplatin oral platinum cancer therapy, which is partnered with NeoTherapeutics Inc....
BioCentury | May 19, 2003
Finance

Ebb & Flow

...initial Phase II data in June for satraplatin , an oral platinum chemotherapeutic in-licensed from NeoTherapeutics...
BioCentury | Apr 21, 2003
Finance

Ebb & Flow

...to investors about its new focus on satraplatin , an oral platinum chemotherapeutic in-licensed from NeoTherapeutics...
BioCentury | Dec 9, 2002
Clinical News

NeoTherapeutics preclinical data

...effects associated with Ritalin. Data were presented at the Society for Neuroscience meeting in Orlando. NeoTherapeutics Inc....
BioCentury | Dec 9, 2002
Clinical News

NeoTherapeutics preclinical data

...antipsychotic treatments. NEOT said both compounds had improved safety profiles compared to clozapine and risperidone. NeoTherapeutics Inc....
Items per page:
1 - 10 of 143